Evaluation of Famciclovir vs. Placebo on Herpes Zoster Induced Pain (including Post-Herpetic), A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study, SmithKline Beecham, Protocol FAM-067: 1/93 – 6/93. Co-Investigator.

Dirithromycin vs. Erythromycin in Skin and Soft Tissue Infections, Lilly/Pharmaco Dynamics, Protocol B9Z-MC-AQAX: 1/93 – 6.93. Co-Investigator.

A Comparison Study of the Efficacy and Safety of Augmentin 500/125 mg p.o. q 12 hrs. and Augmentin 250/125 mg p.o. q 8 hrs. in the Treatment of Uncomplicated Skin and Skin Structure Infections, SmithKline Beecham, Protocol 983-013: 7/92 – 2/93. Co-Investigator.

A Double-Blind, Parallel Group Study of the Efficacy and Safety of BMS 181161 (Calcipotriene – A Vitamin D3 Analogue) Ointment 0.005% vs. its Vehicle in the Treatment of Plaque Psoriasis in a Pediatric Population, Bristol-Myers Squibb, Protocol DE127-014-006: 3/92 – 2/93. Co-Investigator.

A Double-Blind, Randomized, Comparative Multicenter Study of CI-983 vs. Cephalexin in the Treatment of Skin and Skin Structure Infections (Pediatric Population), Warner-Lambert/Parke Davis, Protocol CI9830013: 6/92 – 6.93. Co-Investigator.

Fusidic Acid vs. Erythromycin in the Treatment of Bacterial Folliculitis, Bristol-Myers Squibb, Protocol DE125-002: 1/92 – 6/93. Co-Investigator.

A Double-Blind, Randomized, Placebo-Controlled Parallel Group Study to Assess the Safety and Efficacy of Oral BRL 42810 in the Treatment of Patients with Uncomplicated 

Herpes Zoster. SmithKline Beecham Pharmaceuticals, Protocol 42810/008: 5/91-6/93. Co-Investigator.

A Double Blind, Randomized, Comnparative, Multicenter Study of CI-983 (Cefdinir) vs. Cephalexin in the Treatment of Skin and Skin Structure Infections. Parke-Davis Research Division, Protocol 983-8-19: 3/92 – 12/92. Co-Investigator.

Safety and Efficacy of AGN 190168 in the Treatment of Acne Vulgaris: AGN 190168 0.1% and 0.5% Gels vs. Vehicle Gel. Herbert Laboratories, Protocol R168-220-7997. 1/17/92 – 6/18/92. Co-investigator.

A Multicenter, Double-Blind Evaluation of Recombinant Human Basic Fibroblast Growth Factor in the Treatment of Diabetic Ulcers. Pharmaco Dynamics Research, Inc., Protocol SID-03/SY02-C90-WH04: 3/5/91 – 1/23/92. Co-Investigator.

A Multicenter, Double-Blind Evaluation of Recombinant Human Basic Fibroblast Growth Factor in the Treatment of Venous Stasis and Diabetic Ulcers. Pharmaco Dynamics Research, Inc./Synergen, Inc., Protocol SID-9-03: 7/1/90 – 10/16/91. Co-Investigator.

A Comparison of the Safety and Efficacy of Lomefloxacin and Ciprofloxacin in the Treatment of Non-Necrotizing Skin and Skin Structure Infections. G.D. Searle and Co., Protocol S69-90-02-189: 2/26/91 – 5/2/91. Co-Investigator.

Comparative Safety and Efficacy of Clarithromycin and Cefadroxil Suspensions in the Treatment of Children with Mild to Moderate Skin or Skin Structure Infection. Abbott Laboratories, Protocol M90-491. 11/19/90 – 7/8/91. Co-Investigator.

A Multicenter, Double-Blind, Vehicle Controlled Study of Topical 5% Spironolactone Cream in the Treatment of Nodulocystic Acne. G.D. Searle and Co., Protocol S84-90-02-016: 3/16/90 – 10/5/90. Co-Investigator.

A Multicenter Open Label Study of the Long Term Safety of Topical 5% Spirononlactone Cream in the Treatment of Facial Acne Vulgaris. G.D. Searle and Co., Protocol S84-89-02-019 (Continuation of S84-89-02-014): 4/13/90 – 9/4/90. Co-Investigator.